Neurofilament Light Chain (NfL) is a critical cytoskeletal protein primarily expressed in large myelinated axons, where it plays an essential role in maintaining axonal structural integrity and caliber. In neurodegenerative diseases, NfL has emerged as one of the most promising axonal damage biomarkers, detectable in cerebrospinal fluid (CSF) and blood. Elevated NfL levels reflect the degree of axonal injury across a spectrum of neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS). [1]
Neurofilaments are intermediate filaments that constitute a major component of the neuronal cytoskeleton. The neurofilament triplet consists of three subunits: [2]
NfL serves as the foundational scaffold onto which NfM and NfH assemble to form the mature neurofilament heteropolymer. The protein is encoded by the NEFL gene located on chromosome 8p21.2 and is expressed predominantly in large-diameter axons of motor and sensory neurons. [3]
In healthy neurons, neurofilaments provide structural support for axonal transport and help maintain the diameter of large myelinated axons, which directly correlates with conduction velocity. NfL is phosphorylated at specific serine and threonine residues, which modulates its assembly dynamics and interaction with other cytoskeletal proteins. [4]
NfL is released into extracellular spaces and subsequently into CSF and blood through a well-characterized sequence of events: [5]
In Alzheimer's disease, NfL levels correlate with: [6]
Multiple studies have demonstrated that CSF NfL increases 10-15 years before clinical diagnosis in individuals with autosomal dominant AD mutations. [7]
Key references: Mattsson et al. (2019)[1:1], Preische et al. (2019)[2:1]
In Parkinson's disease, NfL serves as: [8]
Elevated NfL in PD correlates with: [9]
Key References:
NfL is particularly elevated in ALS, where it:
CSF NfL in ALS can be 5-10x higher than in healthy controls, making it one of the most robust biomarkers for this condition.
Key References:
In FTD, NfL:
In MS, NfL serves as:
| Disease | Diagnostic Utility | Sensitivity | Specificity |
|---|---|---|---|
| ALS | High | 85-90% | 80-85% |
| MS (active disease) | High | 70-80% | 75-85% |
| AD (prodromal) | Moderate | 60-70% | 70-80% |
| PD (with dementia) | Moderate | 65-75% | 70-80% |
| FTD | Moderate | 60-70% | 75-85% |
While NfL itself is not a direct therapeutic target, understanding its dynamics has led to:
Several clinical trials now incorporate NfL as:
Key References:
NfL intersects with numerous other neurodegenerative mechanisms:
Neurofilament Light Chain represents one of the most validated and clinically useful biomarkers in neurodegenerative disease. Its release reflects the fundamental pathological process of axonal injury that underlies virtually all neurodegenerative conditions. As assay technologies continue to improve and clinical experience accumulates, NfL is poised to become a routine part of the neurodegenerative disease diagnostic and monitoring armamentarium.
Mattsson et al. CSF and plasma neurofilament light chain in preclinical AD (JAMA Neurology, 2019). 2019. ↩︎ ↩︎
Preische et al. Serum neurofilament dynamics predicts neurodegeneration in preclinical AD (Nature Medicine, 2019). 2019. ↩︎ ↩︎
Benatar et al. Neurofilament light chain in ALS (Lancet Neurology, 2018). 2018. ↩︎
Pilotto et al. Serum neurofilament light chain in Parkinson's disease (Neurology, 2019). 2019. ↩︎
Khalil et al. 'Neurofilament light chain: a biomarker for neurodegeneration (Nature Reviews Neurology, 2018)'. 2018. ↩︎
Giovannelli et al. CSF neurofilament light chain in ALS (Annals of Neurology, 2022). 2022. ↩︎
Mollenhauer et al. Neurofilament light chain in Parkinson's disease progression (Parkinsonism and Related Disorders, 2021). 2021. ↩︎
Bacioglu et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and AD (Cell, 2016). 2016. ↩︎
Zetterberg & Blennow, Neurofilament light chain in CSF and blood (Annals of Clinical and Translational Neurology, 2020). 2020. ↩︎